Theratechnologies appoints executive for clinical affairs

Montreal, QC – Biotechology company Theratechnologies says it has appointed Dr James W Sutton as vice president, clinical development and regulatory affairs. Dr Sutton will oversee all preclinical, clinical and regulatory activities of the company.

“Dr Sutton brings us valuable clinical and regulatory experience from the pharmaceutical industry in the United States and Canada,” says Yves Rosconi, the company’s president and chief executive officer. "His accomplishments include the planning and completion of numerous clinical research studies from Phase I through to Phase IV, and direct involvement in the preparation of successful regulatory submissions, notably in the United States."

Dr Sutton earned his BSc from St Francis Xavier University in Canada and his medical degree from the University of the West Indies in Jamaica. Following graduation from medical school, he gained clinical experience in the West Indies before taking on the role of medical director at the Farrington Medical Centre, Anguilla, WI. He then pursued a career in Canada’s pharmaceutical industry focused on clinical research. This field took him quickly to the United States where he occupied positions of increasing responsibility with GD Searle & Company, Rhone-Poulenc Rorer, Bayer and Schering. Prior to joining Theratechnologies, he was vice president at Procyon Biopharma.